These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 11454537)
1. Polycythemia vera and essential thrombocythemia with monoclonal gammopathy: experience of a single institution. Randi ML; Tison T; Zelante A; Ruzzon E; Girolami A Haematologica; 2001 Jul; 86(7):769-70. PubMed ID: 11454537 [No Abstract] [Full Text] [Related]
2. Association of monoclonal gammopathy and polycythemia vera or essential thrombocythemia: study of a large cohort of patients. Randi ML; Tison T; Ruzzon E; Pacquola E; Girolami A Ann Hematol; 2003 Apr; 82(4):214-7. PubMed ID: 12707723 [TBL] [Abstract][Full Text] [Related]
3. Aspirin-responsive painful red, blue, black toe, or finger syndrome in polycythemia vera associated with thrombocythemia. Michiels JJ; Berneman Z; Schroyens W; van Urk H Ann Hematol; 2003 Mar; 82(3):153-9. PubMed ID: 12634947 [TBL] [Abstract][Full Text] [Related]
4. 6-Thioguanine treatment of uncontrolled thrombocytosis in polycythemia vera and essential thrombocythemia. Delfini C; Porcellini A; Izzi T; Baronciani D Haematologica; 1984; 69(6):766-7. PubMed ID: 6441754 [No Abstract] [Full Text] [Related]
5. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Gerli G; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Marchioli R; Leone G; Barbui T; Haematologica; 2008 Mar; 93(3):372-80. PubMed ID: 18268279 [TBL] [Abstract][Full Text] [Related]
6. Summaries for patients. Polycythemia vera and essential thrombocythemia in a general population. Ann Intern Med; 2003 Sep; 139(6):I32. PubMed ID: 13679345 [No Abstract] [Full Text] [Related]
7. Characteristic changes in platelet-large cell ratio, lactate dehydrogenase and C-reactive protein in thrombocytosis-related diseases. Kabutomori O; Kanakura Y; Iwatani Y Acta Haematol; 2007; 118(2):84-7. PubMed ID: 17622783 [TBL] [Abstract][Full Text] [Related]
8. Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia. Johansson P Semin Thromb Hemost; 2006 Apr; 32(3):171-3. PubMed ID: 16673273 [TBL] [Abstract][Full Text] [Related]
9. [Cerebrovascular disease in aged patients with polycythemia or thrombocythemia]. Akiguchi I; Shio H; Suzuki G; Kameyama M Nihon Ronen Igakkai Zasshi; 1985 Mar; 22(2):93-9. PubMed ID: 4010043 [No Abstract] [Full Text] [Related]
11. Mutation of the prothrombin gene and thrombotic events in patients with polycythemia vera or essential thrombocythemia: a cohort study. Gisslinger H; Müllner M; Pabinger I; Heis-Vahidi-Fard N; Gisslinger B; Brichta A; Bachleitner-Hofmann T; Mannhalter C Haematologica; 2005 Mar; 90(3):408-10. PubMed ID: 15749677 [TBL] [Abstract][Full Text] [Related]
12. Splenectomy after portal thrombosis in patients with polycythemia vera and essential thrombocythemia. Randi ML; Fabris F; Ruzzon E; Pacquola E; Cella G; Girolami A Haematologica; 2002 Nov; 87(11):1180-4. PubMed ID: 12414348 [TBL] [Abstract][Full Text] [Related]
13. Essential thrombocythaemia and polycythaemia vera presenting with pulmonary embolism mimicing pneumonia. Case reports. Björkholm M; Mellstedt H; Säwe U Haematologica; 1981 Oct; 66(5):667-72. PubMed ID: 6796474 [No Abstract] [Full Text] [Related]
14. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Passamonti F; Rumi E; Pungolino E; Malabarba L; Bertazzoni P; Valentini M; Orlandi E; Arcaini L; Brusamolino E; Pascutto C; Cazzola M; Morra E; Lazzarino M Am J Med; 2004 Nov; 117(10):755-61. PubMed ID: 15541325 [TBL] [Abstract][Full Text] [Related]
15. Erythrocytosis, thrombocytosis, and rate of recurrent thromboembolic event-A population based cohort study. Larsson AE; Andréasson B; Holmberg H; Liljeholm M; Själander A Eur J Haematol; 2023 Jun; 110(6):608-617. PubMed ID: 36725666 [TBL] [Abstract][Full Text] [Related]
16. Pathogenesis and management of bleeding in essential thrombocythemia and polycythemia vera. Elliott MA; Tefferi A Curr Hematol Rep; 2004 Sep; 3(5):344-51. PubMed ID: 15341701 [TBL] [Abstract][Full Text] [Related]
17. Trends in the incidence of chronic Philadelphia chromosome negative (Ph-) myeloproliferative disorders in the city of Göteborg, Sweden, during 1983-99. Johansson P; Kutti J; Andréasson B; Safai-Kutti S; Vilén L; Wedel H; Ridell B J Intern Med; 2004 Aug; 256(2):161-5. PubMed ID: 15257729 [TBL] [Abstract][Full Text] [Related]
18. Triangular approach for the diagnosis of monoclonal gammopathy in malignancies. Kulkarni SA; Shrikhande AV Indian J Cancer; 2002 Jun; 39(2):45-54. PubMed ID: 12789724 [TBL] [Abstract][Full Text] [Related]
19. Safety profile of hydroxyurea in the treatment of patients with Philadelphia-negative chronic myeloproliferative disorders. Randi ML; Ruzzon E; Luzzatto G; Tezza F; Girolami A; Fabris F Haematologica; 2005 Feb; 90(2):261-2. PubMed ID: 15710584 [TBL] [Abstract][Full Text] [Related]
20. Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms. Vannucchi AM; Masala G; Antonioli E; Chiara Susini M; Guglielmelli P; Pieri L; Maggi L; Caini S; Palli D; Bogani C; Ponziani V; Pancrazzi A; Annunziato F; Bosi A Cancer Epidemiol Biomarkers Prev; 2009 Jul; 18(7):2068-73. PubMed ID: 19531676 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]